Now more than ever, exosome and EV therapies are on the verge of groundbreaking clinical and commercial breakthroughs. With recent milestones like Aegle Therapeutics' clinical advances, Kimera Labs' FDA approval, Capricor Therapeutics' collaboration on a COVID vaccine with the NIH, and NurExone Biologics' innovations in CNS treatments, this summit is a must-attend event. Join us at the 6th Exosome-Based Therapeutics Development Summit in September to delve into groundbreaking advancements, access exclusive clinical data, and forge pivotal partnerships to define the future of exosome drug development. 

Spanning the complete development cycle of exosome therapeutics from discovery through IND filing, our summit uniquely integrates cutting-edge research with practical commercialization strategies. It stands as the sole industry meeting that bridges the gap between science and business, propelling clinical advancements. 

Don't miss the chance to connect with over 150 of the industry's leading experts in exosome therapeutics, gain invaluable insights, and place your work at the forefront of pharmaceutical innovation. Join us at the 6th Exosome-Based Therapeutics Development Summit and contribute to the evolving landscape of advanced extracellular vesicle drug development.

URLs:

Tickets: https://go.evvnt.com/2433871-2?pid=91

Brochure: https://go.evvnt.com/2433871-3?pid=91

Prices:

Conference + 3 Workshops (Full Access) - Industry Pricing: USD 4197.00,

Conference Only - Industry Pricing: USD 2999.00,

Conference + 3 Workshops (Full Access) - Academic Pricing: USD 3597.00,

Conference Only - Academic Pricing: USD 2599.00,

Conference + 3 Workshops (Full Access) - Service Provider Pricing: USD 5097.00,

Conference + Only - Service Provider Pricing: USD 3699.00

Speakers: AJ Bergmann Chief Financial Officer Capricor Inc., Banishree Saha Associate Director Takeda Pharmaceutical Co. Ltd., Carla Mazzeo Research and Development Director Regenerelle, Celine Larkin Scientist OmniSpirant, Christine Happel Program Director National Cancer Institute, Chulhee Choi President ILIAS Biologics Inc., Driton Vllasaliu MPharm Course Director Kings College University, Gary Hao Vice President - Chemistry, Manufacturing and Controls Vesigen Therapeutics, Gerardo Rodriguez Chief Scientific and Medical Officer Exosome Therapeutics, Gi-Hoon Nam Co-Founder and Chief Executive Officer SHIFTBIO INC. and Korea University College of Medicine, Heidi Kempinski Chief Operating Officer Aegle Therapeutics, Hugues Wallemacq Chief Operating Officer EXO Biologics, Jahan Jowharchi Chief of Technical Operations RION Health, Jean-Paul Prieels Chief Executive Officer convEyXO SA, Jill Swartz Chief Product Officer ZeoScientific, Lexie Shannon Holliday Associate Professor University of Florida, Linda Marban Chief Executive Officer Capricor Inc., Mansoor Amiji University Distinguished Professor Northeastern University, Mercedes Kweh CEO Kwehealth, MICHAEL DOHERTY Associate Director - Process Development Ring Therapeutics, Nazma Ilahibaks Founder Jama Therapeutics, Nicolas Rousseau Chief Operating Officer EVerZom, Patricia Freire Research and Development Innovation Manager Exogenus Therapeutics, Qin Yu Vice President - Research Vesigen Therapeutics, Rob Knight Lead Scientist Cellese, Robin Smith Co-Founder Exotropin, Tong Zhao Chief Executive Officer TheraXyte Bioscience, Tony Hu Presidential Chair and Professor Tulane University, Viviana Hamilton Director, CMC ArunA Bio, Xenia Sango CEO and MD VivaZome Therapeutics, Yujia Jing Senior Director Xsome